Menu
Not yet recruiting NCT06676397

Homeostatic Roles of Eosinophils in Asthma

No phase Interventional Asthma; Eosinophilic

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Blood Punction.
Who it may be relevant to
Registry conditions: Asthma; Eosinophilic. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Characterization of the Homeostatic Functions of Eosinophils in Asthma: An Exploratory Study

Overview

The HOMEOS study is an exploratory, observational, and monocentric research. It focuses on characterizing the homeostatic roles of eosinophils in severe asthma. The primary objective is to identify eosinophil subpopulations among different groups of severe asthmatic patients using flow cytometry. The study aims to advance understanding of eosinophil diversity, which could guide new therapeutic approaches .

Interventions

  • Procedure Blood Punction
    venous blood sampling

Primary outcome measures

  • Flow cytometry based eosinophil phenotyping : Expression levels of cell markers CD62L, CD123, CD101, CD11b, CD193, CD125, Siglec-8 on blood eosinophils quantified by flow cytometry and expressed in % and MFI (mean fluorescence intensity) [Time frame: at inclusion]

Eligibility criteria

Inclusion criteria

  • Patients diagnosed with mild asthma with severe asthma (Biologic-naïve, responders to anti-eosinophil biologic therapies and resistant to anti-eosinophil biologic therapies), control subjects without asthma
  • Signature of informed consent
  • Affiliation with the French social security system

Exclusion criteria

  • Non-eosinophilic asthma
  • Coexistence of a chronic eosinophilic inflammatory condition other than asthma
  • Other respiratory conditions (cystic fibrosis, COPD, allergic bronchopulmonary aspergillosis, etc.)
  • Treatment with corticosteroids within 10 days prior to inclusion
  • Active smoking or a smoking history of more than 20 pack-years
  • Pregnant women
  • Legal incapacity or limited legal capacity
  • Subject unlikely to cooperate with the study and/or with anticipated low cooperation as assessed by the investigator
  • Subject without health insurance
  • Subject currently in an exclusion period of another study or as indicated by the "national registry of volunteers."

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Non-randomized
Model
Single group
Masking
Open label
Primary purpose
Other

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT06676397 · 2024/877

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗